Factors Affecting Survival in Operated Esophageal Squamous Cell Carcinoma.

Autor: Akgul N; Department of Internal Medicine, Yuzuncu Yil University Medical School, 65030, Van, Turkey. dr.nidaakgul@gmail.com., Sakin A; Department of Medical Oncology, Yuzuncu Yil University Medical School, 65030, Van, Turkey., Sahin S; Department of Medical Oncology, Van Research and Training Hospital, Van, Turkey., Aldemir MN; Department of Medical Oncology, Yuzuncu Yil University Medical School, 65030, Van, Turkey., Aytekin A; Department of Medical Oncology, Yuzuncu Yil University Medical School, 65030, Van, Turkey., Alay M; Department of Internal Medicine, Yuzuncu Yil University Medical School, 65030, Van, Turkey., Iliklerden UH; Department of General Surgery, Van Research and Training Hospital, Van, Turkey., Kotan MC; Department of General Surgery, Van Research and Training Hospital, Van, Turkey.
Jazyk: angličtina
Zdroj: Journal of gastrointestinal cancer [J Gastrointest Cancer] 2022 Jun; Vol. 53 (2), pp. 439-445. Date of Electronic Publication: 2021 Mar 31.
DOI: 10.1007/s12029-021-00631-z
Abstrakt: Purpose: Esophageal squamous cell carcinoma (ESCC) is an extremely fatal and relatively rare gastrointestinal system malignancy. This study aimed to investigate the factors affecting survival in operated patients with ESCC.
Materials and Methods: We included 110 patients (38 [34.5%] male; 72 [65.5%] female) aged ≥ 18 (median age, 54 [26-77]) years who were operated without any signs of metastases and followed up at Van Yüzüncü Yıl University Dursun Odabaşı Medical Center between 2004 and 2019.
Results: Initially, 39 (35.5%) patients were clinical lymph node-positive and 71 (64.5%) patients were negative. Thirty-five (31.8%) patients underwent surgery after neoadjuvant chemoradiotherapy (nCRT), and 75 (%68.2) patients underwent direct surgery without nCRT. Five-year overall survival (OS) was 84.4% and 59.2% in patients who underwent surgery after nCRT and in those who underwent direct surgery, respectively. Median OS was significantly longer in patients who underwent surgery after nCRT (p = 0.003). There was a statistically significant difference in OS in patients who underwent surgery after nCRT depending on tumor response (p = 0.04). In multivariate analysis, advanced pathologic stage (p = 0.002) adversely affected survival, whereas nCRT administration (p = 0.031) positively affected OS.
Conclusion: We suggest that nCRT should be administrated before surgery, especially in locally advanced ESCCs. In addition, we believe that nCRT response can be used as a good parameter for survival. These results, however, should be supported by prospective studies.
(© 2021. Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: